MedTrace Logo

Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration

NCT02511613 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2017-04-27

No results posted yet for this study

Summary

The purpose of this study is to evaluate anatomical and functional effect of combination therapy of Squalamine Lactate Ophthalmic Solution, 0.2% administered twice daily with monthly ranibizumab intravitreal injections in patients with choroidal neovascularization due to AMD.

Conditions

  • Age-Related Macular Degeneration

Interventions

DRUG

Squalamine Lactate Ophthalmic Solution, 0.2%

Squalamine Lactate Ophthalmic Solution, 0.2% administered BID

DRUG

Placebo Ophthalmic Solution

Placebo Ophthalmic Solution, administered BID

DRUG

ranibizumab

ranibizumab intravitreal injection

Sponsors & Collaborators

  • Ohr Pharmaceutical Inc.

    lead INDUSTRY

Principal Investigators

  • Avner Ingerman, MD · Ohr Pharmaceutical

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2016-04-30
Completion
2016-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02511613 on ClinicalTrials.gov